Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys

Daniel E. Casey

Research output: Contribution to journalArticlepeer-review

55 Scopus citations


The ability of dopamine D1 antagonists to produce acute extrapyramidal syndromes (EPS) in nonhuman primates is unclear. Some studies in monkeys show that D1 antagonists produce acute dystonia, whereas other studies do not report these effects. The central issues that have yielded conflicting results revolve around prior treatment status (neuroleptic-naive versus neuroleptic sensitized) and route of administration (oral versus parenteral). In this study, separate groups of neuroleptic drug-naive cebus monkeys were tested once weekly with intramuscularly administered SCH 23390, a D1 antagonist, or haloperidol, a D2 antagonist, across a dose range of 0.01-0.25 mg/kg, and a saline control. Both active drugs, but not saline, produced clinically identical syndromes of acute dystonia and bradykinesia, though haloperidol induced higher symptom scores over a longer duration. Sedation and locomotor activity were unchanged by SCH 23390, but decreased with haloperidol. Factors regarding acute EPS liability in nonhuman primate models and clinical implications in man are discussed.

Original languageEnglish (US)
Pages (from-to)18-22
Number of pages5
Issue number1
StatePublished - May 1992
Externally publishedYes


  • Dopamine receptor subtypes
  • Extrapyramidal syndromes
  • Haloperidol
  • Neuroleptics
  • Nonhuman primates
  • SCH 23390

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys'. Together they form a unique fingerprint.

Cite this